International Journal of Pediatrics / 2013 / Article / Tab 1

Clinical Study

Doxapram Use for Apnoea of Prematurity in Neonatal Intensive Care

Table 1

Patient characteristics of included premature neonates who received doxapram (Total ).

Overall ( )Successfully treated patients ( )Unsuccessfully treated patients ( )
PercentageMedian (IQR)PercentageMedian (IQR)PercentageMedian (IQR)

Birth weight (gram)937 (267)980 (267)915 (332)0.21
Gestational age (weeks)27 (1.7)27 (2.2)27 (2.6)0.21
Apgar score
 1 min5 (4)6 (4)5 (4)0.09
 5 min8 (2)8 (2)8 (2)0.08
Mode of delivery:
 Caesarean section33.3%32.0%38.9%
Maternal corticosteroids
Centre1/centre 268.9%/31.1%69.2%/65.8%30.8%/34.2%
Gender (m/f)50%/50%49.4%/50.6%54.1/45.9%
Twin 35.2%41.7%24.3%
Primary ventilation37.7%27.8%56.8%
Ventilation before doxapram80.7%76.3%86.5%
Surfactant therapy 74.6%67.1%86.1%
Caffeine 98.3%98.7%97.3%
Theophylline 32.0%31.6%29.7%

Maternal corticosteroid therapy was judged adequate if two doses were given more than 24 hours before birth.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.